MET and neoplasm: Of the tumor samples, 13 harbored ALK fusion mutations, 5 harbored ROS1 fusion mutations, 2 harbored RET fusion mutations, 6 contained MET exon14 skipping mutations, and 8 were negative controls (Table 2).